Issue 78, 2022

SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy

Abstract

A new conjugate formulation, SIWV-PB-SN, based on glioblastoma (GBM)-homing SIWV tetrapeptide and an ROS-responsive prodrug is reported. SIWV-PB-SN selectively penetrates the GBM cells and releases anti-GBM drug (SN-38) via ROS-induced linker cleavage. This study presents a new insight for a more advanced therapeutic approach to overcoming GBM.

Graphical abstract: SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy

Supplementary files

Article information

Article type
Communication
Submitted
07 Maw 2022
Accepted
01 Ndz 2022
First published
09 Ndz 2022

Chem. Commun., 2022,58, 10941-10944

SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy

Y. K. Park, P. Jangili, S. Zi, R. H. Kang, D. Kim and J. S. Kim, Chem. Commun., 2022, 58, 10941 DOI: 10.1039/D2CC03777G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements